Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276), through its subsidiaries, received approval from China's National Medical Products Administration for the clinical trials of a drug combination for bladder cancer, according to a Shanghai bourse filing on Tuesday.
The subsidiaries, Suzhou Shengdiya Biopharmaceutical, Shanghai Shengdi Pharmaceutical and Shanghai Hengrui Pharmaceutical, obtained authorization to trial SHR-2005 in combination with SHR-1501, with or without adebrelimab.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments